A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in
patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus
severity score over the first week of treatment
A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)
Merck Sharp & Dohme Corp.
This study was a double-blind, placebo-controlled, cross-over, single-center study of
desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of
seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of
desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis
induced by direct conjunctival challenges with a previously identified sensitizing antigen,
in the eyes of a subject known to be sensitive to the antigen.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.